-
Study Casts More Doubt on Value of Mammograms
drugs.com
January 10, 2017
Mammograms frequently detect small breast tumors that might never become life-threatening, causing women to receive treatment they likely don't need, a new Danish study finds.
-
Catalent to Evaluate JOTROL for Softgel Delivery
contractpharma
January 10, 2017
Will assess different softgel delivery technologies to overcome poor bioavailability
-
Amgen, DaVita Enter New Sourcing And Supply Agreement - See more at: http://www.contractpharma.com/c
January 10, 2017
Amgen will supply EPOGEN and Aranesp for dialysis services in the U.S. and Puerto Rico
-
Interview: Roche discusses the importance of sustainability in pharma manufacturing
pharmafile
January 09, 2017
Peter Schurrenberger, Chief Safety, Health and Environment Officer at Roche, discusses their recent recognition as a leader for corporate action on climate change by the CDP.
-
Aurobindo Pharma gets US FDA nod for its anti-epileptic drug and to acquire Portugal’s Generis for €
firstwordpharma
January 09, 2017
Aurobindo Pharma has been granted final FDA approval to launch a generic version of HQ Specialty Pharma's epilepsy drug levetiracetam, livemint.com reported, Aurobindo Pharma to acquire Portugal’s Generis for €135 million.
-
Mast Therapeutics And Savara Sign Merger Agreement
firstwordpharma
January 09, 2017
Proposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases
-
Amyris Names Kathleen Valiasek CFO
contractpharma
January 09, 2017
Senior finance and business veteran with Fortune 500 experience joins company.
-
Eurofins Acquires Villapharma in Spain
contractpharma
January 09, 2017
Expands footprint in discovery pharmacology .
-
Synthetic Genomics Announces Collaboration with Johnson & Johnson Innovation to Develop Novel Therap
americanpharmaceuticalreview
January 09, 2017
Synthetic Genomics has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to apply Synthetic Genomics' proprietary replicon RNA technology toward th
-
Takeda and PvP Biologics Form $35M GI Pact
contractpharma
January 09, 2017
Deal centers around novel therapeutic for celiac disease